Jiang, Sibo
Pfizer (United States)
2 papers on CoChat
Most cited papers
- Verified
Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
Raje, N., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., et al. (2022) · Blood
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 46
- Verified
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
Jakubowiak, A. J., Bahlis, N. J., Raje, N. S., Costello, C., Dholaria, B. R., Solh, M. M., Levy, M. Y., Tomasson, M. H., Dube, H., Damore, M. A., et al. (2022) · Journal of Clinical Oncology
Multiple Myeloma Research and TreatmentsCAR-T cell therapy research
Cited by 16
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free